Literature DB >> 33751649

Blinatumomab vs historic standard-of-care treatment for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukaemia.

.   

Abstract

Entities:  

Year:  2021        PMID： 33751649      PMCID： PMC8173652          DOI： 10.1111/ejh.13575

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN： 0902-4441            Impact factor:   2.997


× No keyword cloud information.
  2 in total

1.  Blinatumomab vs historic standard-of-care treatment for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukaemia.

Authors: 
Journal:  Eur J Haematol       Date:  2021-01-25       Impact factor: 2.997

2.  Blinatumomab vs historic standard-of-care treatment for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukaemia.

Authors:  Nicola Gökbuget; Hervé Dombret; Sebastian Giebel; Monika Brüggemann; Michael Doubek; Robin Foa; Dieter Hoelzer; Christopher Kim; Giovanni Martinelli; Elena Parovichnikova; Josep Maria Ribera; Marieke Schoonen; Catherine Tuglus; Gerhard Zugmaier; Renato Bassan
Journal:  Eur J Haematol       Date:  2020-01-24       Impact factor: 2.997
  2 in total
  1 in total

1.  Blinatumomab vs historic standard-of-care treatment for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukaemia.

Authors: 
Journal:  Eur J Haematol       Date:  2021-01-25       Impact factor: 2.997
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.